Analysts Offer Insights on Healthcare Companies: Ziopharm Oncology (NASDAQ: ZIOP) and Amarin (NASDAQ: AMRN)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ziopharm Oncology (NASDAQ: ZIOP) and Amarin (NASDAQ: AMRN) with bullish sentiments.

Ziopharm Oncology (NASDAQ: ZIOP)

H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage with a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP) today and set a price target of $9.50. The company’s shares closed yesterday at $5.85.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -18.0% and a 23.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.

Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.

Amarin (NASDAQ: AMRN)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Amarin (NASDAQ: AMRN), with a price target of $10. The company’s shares closed yesterday at $2.94.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.5% and a 45.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Amarin has an analyst consensus of Strong Buy, with a price target consensus of $6.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.